Barinthus Biotherapeutics (BRNS) Depreciation & Amortization (CF) (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $856000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 57.92% year-over-year to $856000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 27.12% YoY) and the FY2025 annual result came in at $5.8 million, up 0.78% from the prior year.
• Depreciation & Amortization (CF) retreated to $856000.0 in Q1 2026, from $909000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q1 2025 to a low of $856000.0 in Q1 2026.
• A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 1297.65% — and 2026, when it sank 57.92%.
• Tracing BRNS's Depreciation & Amortization (CF) over 5 years: stood at $1.2 million in 2022, then advanced by 21.92% to $1.4 million in 2023, then dropped by 0.49% to $1.4 million in 2024, then slumped by 36.34% to $909000.0 in 2025, then retreated by 5.83% to $856000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $856000.0 (Q1 2026), $909000.0 (Q4 2025), and $901000.0 (Q3 2025), per Business Quant data.